ThyroTrack (Thyroid Prognostication Test)

Detects genomic biomarkers from FNAC fluid or FFPE tissue to guide prognosis and clinical management

Connect with Our Experts

To Book a Test,
Call 1800 296 9696

What is ThyroTrack?

ThyroTrack is a next-generation sequencing (NGS)-based thyroid tumour test designed to detect genomic biomarkers in thyroid nodules. This thyroid tumour testing uses FNAC (Fine Needle Aspiration Cytology) fluid and FFPE (Formalin-Fixed Paraffin-Embedded) tissue blocks to provide insights into thyroid nodule genetics. This helps in achieving diagnostic accuracy, effective clinical management, and precise surgical decisions.

Book a Test Now

Supports Clinical Decision-Making for the Treating Physician

	Follow Up (Preventing Unneeded Surgery)	Surgery (Personalized Management)
ThyroTrack	Avoiding complications of thyroid surgery. Preserving natural thyroid function. Avoiding long term hormonal supplementation.	Suggests type of surgical management (lobectomy vs. total thyroidectomy). Provides risk of cancer recurrence. Identifies therapeutic targets.

Clinical Indications/Applications of ThyroTrack Test

Thyroid FNA with indeterminate cytology (Bethesda categories III and IV).
Malignant thyroid cytology (Bethesda category V and VI), when results of the NGS are expected to affect the decision for extent of oncological surgery/treatment.
Benign thyroid cytology (Bethesda category II), when strong suspicion of malignancy exists on clinical grounds such as presence of a highly suspicious sonographic pattern.
Bethesda category I nodules which are cytologically insufficient and suspicious on sonographic findings.
When the diagnosis of thyroid cancer is established cytologically or histologically, molecular profiling will affect decision regarding radioactive iodine therapy, intensity of follow up, or for selection of targeted therapies in patients with advanced cancer.
Helps in predicting accurate diagnosis or prognosis of thyroid nodules with indeterminate cytology

Specifications

Indications: Thyroid Cancer: To identify a gene mutation that can affect treatment decisions.
Methodology: Next-Generation Sequencing (NGS).
Sample Type: FNAC fluid in RNA later; Tissue in RNA later; FFPE tissue block.
Accuracy: Limit of Detection: 5% VAF for SNV and InDels, >10 spanning reads for fusions. Average Depth of Sequencing: >250X.
Coverage: SNVs, InDels & Fusions.

ThyroTrack Test Offered by MedGenome

ThyroTrack

Detects: 46 genes analysed for SNVs and InDels, and 23 genes analysed for fusions.
TAT: 14 working Days
Test Code: MGM2538

Key Highlights of MedGenome's ThyroTrack

Diagnostic Importance

Accurate diagnosis of benign category nodules with a clinical suspicion for malignancy.
Stratification of indeterminate nodules into likely benign/likely malignant category.

Pre-Operative Prognostication

Informed decisions on the surgery plans and extent of surgery.

Therapeutic Targets

Detection of therapeutic targets for approved drugs or enrolment into a clinical trial.

Rapid Turnaround Time

Provides results of thyroid cancer screening within 14 working days, facilitating timely clinical decisions.

Guideline Complaince

Interpretation and reporting is done according to NCCN (2022) and ATA guidelines (2015).

Mutation Profiling

Effective in profiling mutations in thyroid nodules with indeterminate cytology, aiding in clearer clinical decision-making.

Comprehensive Reporting

Provides detailed clinical reports with actionable insights for personalised treatment plans.

What is ThyroTrack?

ThyroTrack is an advanced test for detecting the risk of cancer in the thyroid nodule. It looks for specific genetic changes that may lead to the development of cancer. Unlike regular thyroid tests that measure hormone levels, ThyroTrack examines the genetic details of the tumour. This helps in understanding the tumour better and decide on the best treatment or surgery options for the patient.

Book a Test Now

Who Should Get the ThyroTrack Test?

Category	Diagnosis	Outcome
Indeterminate Cytology Results	Bethesda categories III (AUS/FLUS) and IV.	Helps confirm diagnosis and guide surgery decisions.
Suspicious or Malignant Cytology Results	Bethesda categories V and VI.	Useful for planning the extent of surgery and selecting advanced therapies.
Benign Cytology with Suspicious Features	Bethesda category II with highly suspicious ultrasound results.	Aids in ruling out cancer in clinically concerning cases.
Cytologically Insufficient Nodules	Bethesda category I with suspicious sonographic findings.	Helps determine the diagnosis when initial tests are unclear.
Advanced Thyroid Cancer	Molecular profiling helps doctors decide on radioactive iodine therapy, follow-up plans, or targeted treatments.

Laboratory specialist analyzing blood samples, supporting maternal blood group assessment through Rhesus D Track

How Does ThyroTrack Test Differ from Traditional Thyroid Function Tests?

Traditional thyroid function tests measure hormones such as TSH, T3, and T4 to assess thyroid gland activity. While these tests are useful for evaluating general thyroid health, they cannot detect genetic changes in thyroid nodules or tumours.
ThyroTrack, on the other hand, uses advanced genetic sequencing to detect specific genetic changes in thyroid nodules. This makes it a powerful tool for:

Differentiating between cancerous and benign thyroid nodules.
Identifying the risk of cancer recurrence.
Guiding surgical and treatment decisions.

Why Is ThyroTrack Test Needed?

Medical professional verifying clinical details for Rhesus D Track testing

How Does ThyroTrack Help in Differentiating Between Benign and Malignant Thyroid Nodules?

Accurate differentiation is essential for effective treatment. ThyroTrack looks at specific genetic changes to determine if a nodule is cancerous.
For example:

BRAF mutation: Indicates the nodule is very likely to be cancerous.
RAS mutation: Suggests an 84% chance that the nodule is cancerous.
RET and NTRK fusions: Linked to more aggressive types of thyroid cancer.

This information helps doctors recommend appropriate interventions, ensuring the best outcomes for patients.

What Genes Are Covered in the ThyroTrack Gene List?

Advanced medical imaging interface used for clinical evaluation related to Rhesus D Track testing

What Are the Assay Specifications for ThyroTrack?

ThyroTrack has the following specifications:

Sample Requirements:
- Fine Needle Aspiration Cytology (FNAC) fluid or tissue preserved in RNA Later (shipped at 2–4°C).
- FFPE tissue blocks (shipped at room temperature).
Other Specifications:
- Minimum tumour Percentage: 20%.
- Sensitivity: 98% for genetic alterations.
- Methodology: NGS
- Panel Inclusion: 46 Genes (SNVs and InDels), 23 Genes (Fusions)
- Limit of Detection: 5% VAF* for SNV and InDels, >10 spanning reads for fusions
- Turnaround Time: 21 Days

Why Choose MedGenome for Thyroid Tumour Testing?

Get Genetic Counselling by Our Experts

Connect with Our Experts

MedGenome Patient Stories

The couple had previously endured several miscarriages. Further investigations revealed that these losses were due to chromosomal abnormalities (aneuploidies) in the fetus. During their subsequent IVF...

Reproductive Health

Mr. and Mrs. Swamy’s Journey to Paren...

The first reported case of an X-chromosome variant detected by NIPT, confirmed by karyotyping but missed by FISH, involved Savitha (name changed), a 24-year-old woman from...

Reproductive Health

Story of Ms. Savitha

Mr Arjun (name changed) and Ms Shilpa (name changed) are maternal cousins who were planning to get married. There was no significant clinical history suggestive of...

Reproductive Health

The Journey of Mr. Arjun and Ms. Shilpa

Ravi and Swati, a non-consanguineous couple, lost their child on the 52nd day of life. The infant was suspected of having Maple Syrup Urine Disease (MSUD),...

Reproductive Health

Ravi & Swati’s Story

MedGenome in the News

View All

September 12, 2023 5 mins read

NIPT for Twins: What You Should Know?

December 30, 2021 5 mins read

Unlocking Insights: Genetic Tests Every Woman Should Consider

August 21, 2019 5 mins read

A new technology for eradicating TB – MedGenome Labs – Mathrubhumi

Importance of early and accurate diagnosis for Lung Cancer | Dr. C.N. Patil

Inside India’s Largest Genomics Lab | MedGenome’s Multiomics Diagnostics Explained

Karyotyping Reflex Karyoseq Launch – Dr Ashok Khurana

Download SPIT SEQ Brochures

Discover how we can support your wellness through our diverse range of tests. Our brochure provides an in-depth look at our commitment to quality care and patient satisfaction.

Download